Exelus Inc.
USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).
The verdict
According to USPTO PatentsView, Exelus ranks #21,114 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.
- #21,114
- of 49,997 US assignees by volume
- 45th percentile
- by Innovation Score (33.6/100)
- 18.4
- avg claims per patent
- +200%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R21114 · US Corporation #21,114 · 13 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 13 grants
- MID-PACK #21,114/49,997
- PHOTO-FINISH Essex Group
- CPC-NARROW C07C · 5 areas
- INNOV-THIN 33.6/100
- CLAIMS-RICH 18.4 claims/avg
- TYPE-USCORP US Corporation
- VEL-SURGE +200% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Essex Group LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Exelus’s 33.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Exelus
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Exelus · this assignee 34
Exelus · this assignee
34 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Exelus's Innovation Score is 33.6/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Exelus?
Each dot is one of Exelus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Exelus’s own 18.4 claims/patent is ABOVE the 15.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Exelus's grants concentrate
Exelus Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2015. By volume, Exelus sits between Essex Group LLC and FAS Medic S.A..
Exelus's three-year grant acceleration
Exelus Inc. shows 5 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Exelus's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Essex Group
Essex Group LLC
13 patents
- Eta Compute
Eta Compute, Inc.
13 patents
- Evaxion Biotech A…
Evaxion Biotech A/S
13 patents
- Exedy Globalparts
Exedy GlobalParts Corporation
13 patents
- Exoanalytic Solut…
ExoAnalytic Solutions, Inc.
13 patents
- Exponential
Exponential Technologies, Inc.
13 patents
- Eye Drop Imaging…
Eye Drop Imaging Technology, LLC
13 patents
- FAS Medic
FAS Medic S.A.
13 patents
- Exelus ◀
Exelus Inc.
13 patents
What this shows Exelus holds 13 patents at rank #21,113, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Exelus
By rank, the assignees closest to #21,113 in granted patent volume.
- Essex Group LLC #21,109 · 13 patents
- Eta Compute, Inc. #21,110 · 13 patents
- Evaxion Biotech A/S #21,111 · 13 patents
- Exedy GlobalParts Corporation #21,112 · 13 patents
- ExoAnalytic Solutions, Inc. #21,114 · 13 patents
- Exponential Technologies, Inc. #21,115 · 13 patents
- Eye Drop Imaging Technology, LLC #21,116 · 13 patents
- FAS Medic S.A. #21,117 · 13 patents
Leaders in C07C (Acyclic OR Carbocyclic Compounds)
Other assignees with the most granted patents in Exelus's primary technology class.
Exelus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 45th percentile higher than 45% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 7.7% |
| 2019 | 2 | 15.4% |
| 2020 | 1 | 7.7% |
| 2021 | 3 | 23.1% |
| 2022 | 3 | 23.1% |
| 2023 | 1 | 7.7% |
| 2024 | 1 | 7.7% |
| 2025partial year | 1 | 7.7% |
Which technologies does Exelus Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Exelus Inc.'s patent record in context - here's where to go next.
- Exelus Inc.'s lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07C
- Ranked #21,114 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Exelus Inc. against Essex Group LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 33.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.